We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Deepverge Plc | LSE:DVRG | London | Ordinary Share | GB00BMGWZY29 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.15 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDVRG
RNS Number : 4714G
Deepverge PLC
26 July 2021
26 July 2021
AIM share code: DVRG
Deepverge PLC
("Deepverge" or "Company")
Result of Annual General Meeting
Following today's Annual General Meeting ("AGM"), convened by the Notice of AGM dated 2 July 2021, DeepVerge plc is pleased to announce that all resolutions set out in the Notice of AGM were approved by shareholders.
The results of the poll for each resolution were as follows:
Resolution For % For Against % Against Withheld 1. The Company's annual accounts for the 12 months ended 31 December 2020, together with the directors' report and auditor's report thereon, be received and adopted. 34,372,474 99.9% 9,700 0.028% 28,951 ------------ ------- --------- ---------- --------- 2. To re-appoint Jeffreys Henry LLP as auditors. 34,380,263 99.9% 1,611 0.005% 29,251 ------------ ------- --------- ---------- --------- 3. To determine the remuneration of the auditors. 34,372,752 99.9% 11,044 0.032% 27,329 ------------ ------- --------- ---------- --------- 4. To re-elect Nigel Burton as a director of the Company. 34,368,338 99.9% 13,611 0.040% 29,176 ------------ ------- --------- ---------- --------- 5. To re-elect Camillus Glover as a director of the Company. 34,368,129 99.9% 13,820 0.040% 29,176 ------------ ------- --------- ---------- --------- 6. To authorise the directors to allot shares pursuant to Section 551 of the Companies Act 2006. 34,143,623 99.2% 76,963 0.224% 190,539 ------------ ------- --------- ---------- --------- 7. To authorise the directors to allot equity securities (within the meaning of section 560 of the Companies Act 2006) for cash as if section 561 of the Companies Act 2006 did not apply to such allotment. 34,049,883 99.0% 161,722 0.470% 199,520 ------------ ------- --------- ---------- ---------
As at the date of the AGM, the number of issued ordinary shares of the Company was 215,156,378 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, on a poll every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.
Following today's AGM result, a short video will be posted on the Company's website: https://www.deepverge.com/investors
For further information please visit https://www.deepverge.com/or contact:
Enquiries:
+44 (0) 7340 055 DeepVerge plc Gerard Brandon, CEO 648 SPARK Advisory Partners Limited Neil Baldwin/Andrew (Nominated Adviser) Emmott +44 (0) 113 370 8974 Turner Pope Investments (TPI) Limited Andy Thacker/James (Broker) Pope +44 (0) 20 3621 4120
About DeepVerge
DeepVerge plc is a vertically integrated business. It's core skin and human testing technology is built on a clinical based eco-system. Collaboration partners in artificial intelligence, clinical research, medical device and life science contribute to the service management platform. This allows skin-care, health-care, nutritional, pharmaceutical manufacturers and cosmetic companies to test consumer products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company's own skin-care range of products and cannabinoid oils (CBD) sources have been used to test the platform that combines data analytics with access to therapeutic operational expertise offering client solutions ranging from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our laboratory grown living human tissue (Labskin).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGBBGDRXDDDGBL
(END) Dow Jones Newswires
July 26, 2021 07:25 ET (11:25 GMT)
1 Year Deepverge Chart |
1 Month Deepverge Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions